OTCMKTS:ARTH

Arch Therapeutics - ARTH Stock Forecast, Price & News

$0.02

0.00 (-21.00%)

(As of 09/29/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.0151
▼
$0.0195
50-Day Range: $0.02
▼
$0.05
52-Week Range: $0.01
▼
$0.14

Volume: 511,202 shs
Average Volume: 956,329 shs
Market Capitalization: $3.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Arch Therapeutics (OTCMKTS:ARTH) Stock

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.

Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTH Stock News Headlines

September 23, 2022 | finance.yahoo.com

Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support Program

September 16, 2022 | finance.yahoo.com

Arch Therapeutics Announces Intent to Uplist from OTC to a National Exchange

September 7, 2022 | finance.yahoo.com

Arch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound System

July 14, 2022 | benzinga.com

Arch Therapeutics (OTC:ARTH), Short Interest Report

July 7, 2022 | finance.yahoo.com

Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing

June 22, 2022 | finance.yahoo.com

Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel

May 9, 2022 | finance.yahoo.com

Arch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring

April 13, 2022 | finance.yahoo.com

Renowned Wound Care Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Spring

April 4, 2022 | finance.yahoo.com

Arch Therapeutics’ AC5® Advanced Wound System to be Presented at 2022 Symposium on Advanced Wound Care (SAWC) Spring

March 14, 2022 | finance.yahoo.com

Arch Therapeutics Partners with Centurion Therapeutics to Expand Access to AC5® Advanced Wound System

January 6, 2022 | finance.yahoo.com

Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities

January 4, 2022 | finance.yahoo.com

Arch Therapeutics Announces Appointment of Guy Fish to the Board

December 13, 2021 | finance.yahoo.com

Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System

December 1, 2021 | finance.yahoo.com

Arch Therapeutics Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program

November 1, 2021 | finance.yahoo.com

Arch Therapeutics Presents AC5® Advanced Wound System During Innovation Spotlight at 2021 Symposium on Advanced Wound Care (SAWC)

October 25, 2021 | finance.yahoo.com

Arch Therapeutics to Present AC5 Advanced Wound System at 2021 Symposium on Advanced Wound Care (SAWC) Fall

October 18, 2021 | finance.yahoo.com

Arch Therapeutics Launches Experts in Wound Care Program

October 13, 2021 | finance.yahoo.com

Arch Therapeutics Provides Corporate Update

October 6, 2021 | finance.yahoo.com

Arch Therapeutics to Present at the LD Micro Main Event

October 4, 2021 | finance.yahoo.com

Arch Therapeutics Launches Coverage and Reimbursement Pilot

September 30, 2021 | finance.yahoo.com

Arch Therapeutics Announces Appointment of Larry Hicks to the Board

September 2, 2021 | ca.finance.yahoo.com

Arch Therapeutics Partners with Lovell Government Services to Expand Distribution Capabilities

July 12, 2021 | finance.yahoo.com

Arch Therapeutics Completes Leadership Team with Appointment of Dan Yrigoyen as Vice President of Sales

July 7, 2021 | finance.yahoo.com

Arch Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference, July 13 - 14, 2021

June 2, 2021 | finance.yahoo.com

Arch Therapeutics to Present at the LD Micro Invitational XI, June 8 - 10, 2021

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTH Company Calendar

Last Earnings: 7/23/2020
Today: 9/30/2022
Fiscal Year End: 9/30/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:ARTH
Previous Symbol: NASDAQ:ARTH
CUSIP: N/A
CIK: 1537561
Web: www.archtherapeutics.com
Phone: (617) 431-2313
Fax: N/A
Employees: 10
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,240,000.00
Net Margins: -35,372.46%
Pretax Margin: -35,372.46%
Return on Equity: N/A
Return on Assets: -223.22%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.82
Quick Ratio: 0.07

Sales & Book Value

Annual Sales: $10,000.00
Price / Sales: 394.83
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 249,890,000
Free Float: 225,697,000
Market Cap: $3.95 million
Optionable: Not Optionable
Beta: -0.07

Key Executives

Dr. Terrence W. Norchi M.D. (Age 57)
Co-Founder, Chairman, Pres, CEO & Sec.
Comp: $477.53k

Mr. Michael S. Abrams (Age 52)
Chief Financial Officer
Comp: $345.04k

Mr. Daniel M. Yrigoyen (Age 53)
VP of Sales
Comp: $291.73k

Dr. Rutledge Ellis-Behnke Ph.D.
Co-Founder & Scientific Advisor

Dr. Steven A. Kates Ph.D.
VP of Technology

Mr. Daniel C. Wadsworth Jr. (Age 68)
Advisor & Consultant of Wound Care Commercialization

Key Competitors

View All Competitors

ARTH Stock - Frequently Asked Questions

How have ARTH shares performed in 2022?: Arch Therapeutics' stock was trading at $0.0950 at the beginning of the year. Since then, ARTH shares have decreased by 83.4% and is now trading at $0.0158.
View the best growth stocks for 2022 here.
How were Arch Therapeutics' earnings last quarter?: Arch Therapeutics, Inc. (OTCMKTS:ARTH) posted its quarterly earnings data on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.01.
What other stocks do shareholders of Arch Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Sciences (AVXL), POET Technologies (POETF), Aptose Biosciences (APTO), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), Bellerophon Therapeutics (BLPH), Sorrento Therapeutics (SRNE), Biocept (BIOC) and Aurinia Pharmaceuticals (AUPH).

What is Arch Therapeutics' stock symbol?: Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."
How do I buy shares of Arch Therapeutics?: Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Arch Therapeutics' stock price today?: One share of ARTH stock can currently be purchased for approximately $0.02.
How much money does Arch Therapeutics make?: Arch Therapeutics (OTCMKTS:ARTH) has a market capitalization of $3.95 million and generates $10,000.00 in revenue each year.
How can I contact Arch Therapeutics?: Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The official website for the company is www.archtherapeutics.com. The biotechnology company can be reached via phone at (617) 431-2313 or via email at investors@archtherapeutics.com.

This page (OTCMKTS:ARTH) was last updated on 9/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms